JNJ update

I am removing JNJ from my recommended list, because of the litigious environment surrounding drug stocks. Besides the general risks, there are specific risks regarding stents. Further, JNJ recently showed they didn't do due dilligence with the GDT acquisition, as GDT has some litigious risk with their products. For now, I will leave ABT on my recommended list, but it is a candidate for removal, just for the genral risk of lawsuits in the industry.